Last $154.47 USD
Change Today -0.78 / -0.50%
Volume 1.3M
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$155.13
Previous Close
$155.25
Day High
$155.95
Day Low
$153.70
52 Week High
01/9/15 - $172.00
52 Week Low
05/8/14 - $125.37
Market Cap
21.7B
Average Volume 10 Days
1.0M
EPS TTM
$2.91
Shares Outstanding
140.8M
EX-Date
02/25/15
P/E TM
53.0x
Dividend
$0.50
Dividend Yield
0.28%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 10/1/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $563.2K
Executive Vice President of Global Operations...
Total Annual Compensation: $470.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $470.3K
Executive Vice President and General Manager ...
Total Annual Compensation: $458.0K
Compensation as of Fiscal Year 2014.

perrigo co plc (PRGO) Key Developments

Perrigo Company Public Limited Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 04:35 PM

Perrigo Company Public Limited Company Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 04:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Joseph C. Papa, Chairman, Chief Executive Officer and President.

Perrigo Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 27, 2014; Revised Consolidated Earnings Guidance for Fiscal 2015; Provides Earnings Guidance for the Third Quarter of Fiscal 2015

Perrigo Company reported unaudited consolidated earnings results for the second quarter and six months ended December 27, 2014. Net sales in the quarter were $1.07 billion, an increase of 9% over the second quarter of fiscal 2014, primarily attributable to $79 million in incremental sales of Tysabri® from the acquisition of Elan Corporation plc and new product sales of $54 million. This increase was offset partially by lower sales volumes in the contract manufacturing and Animal Health categories within Consumer Healthcare and the VMS and infant foods categories within the Nutritionals segment, as well as a negative foreign exchange impact of $7 million. The company reported net income of $70.2 million or $0.51 per diluted share against net loss of $86.0 million or $0.87 per basic and diluted share a year ago. Operating income was $184.4 against $86.6 a year ago. Income before income taxes was $84.7 million against loss before income taxes of $113.0 a year ago. On Non-GAAP basis, net income of $244.9 million or $1.82 per diluted share against $185.3 million or $1.87 per diluted share a year ago. Income before income taxes was $288.0 million against $214.8 a year ago. Operating income was $316.7 against $237.9 a year ago. Net cash flow from operations for the second quarter was $273 million, up $151 million from the second quarter of fiscal 2014. For the six months, the company reported net income of $166.5 million or $1.23 per basic and diluted share on net sales of $2,023.1 million against net income of $25.3 million or $0.26 per basic and diluted share on net sales of $1,912.4 million a year ago. Operating income was $321.5 against $266.2 a year ago. Income before income taxes was $193.3 million against $44.2 a year ago. Net cash from operating activities was $467.7 million compared to $220.3 million a year ago. Additions to property and equipment were $48.0 million compared to $77.8 million a year ago. On Non-GAAP basis, net income of $432.5 million or $3.22 per diluted share on net sales of $2,023.1 million against net income of $329.1 million or $3.40 per diluted share on net sales of $1,912.4 million a year ago. Income before income taxes was $508.8 million against $421.3 a year ago. Operating income was $564.0 against $464.0 a year ago. The company expects fiscal 2015 consolidated adjusted earnings to be between $7.25 and $7.45 per diluted share as compared to $6.39 in fiscal 2014. This range implies a year-over-year growth rate in adjusted earnings per diluted share of 13% to 17% over fiscal 2014. The company also expects fiscal 2015 reported earnings to be between $3.66 and $3.86 per diluted share as compared to $1.77 in fiscal 2014 and net income-adjusted in range of $978.7 to $1,005.7 million. The company fine-tuned overall Perrigo revenue guidance range for fiscal 2015, which, at the midpoint, indicates consolidated revenues of $4.35 billion, growth of 7% year-over-year and a record for Perrigo. For the third quarter, the company anticipates adjusted net income growth to be in the middle of the updated 32% to 36% annual growth.

Perrigo Company Public Limited Company Declares Quarterly Dividend, Payable on March 17, 2015

Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.125 per share, payable on March 17, 2015 to shareholders of record on February 27, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $154.47 USD -0.78

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,349 INR 0.00
Endo International PLC $85.60 USD +0.36
Hospira Inc $87.54 USD 0.00
Mead Johnson Nutrition Co $104.76 USD +0.41
Mylan Inc/PA $57.33 USD +0.08
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 60.2x
Price/Sales 5.0x
Price/Book 2.2x
Price/Cash Flow 62.8x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.